All tumors were analyzed using an NGS multi-gene panel that expands the tumor genetic portrait, including genes such as BRAF, ERBB2, KRAS, and MET in addition to EGFR and ALK/ROS1, in accordance with recently updated recommendations [8,9]. This evidence concerns the gene MET and neoplasm.